News

The patent covers the innovator’s syringe injection system, which enables users to achieve the correct angle and depth of subcutaneous and intramuscular injections. The ConfiDisc syringe injection system,

Furthermore, Innocoll agrees to grant Merus a right of first refusal for all current pipeline advanced wound care products for the Canadian Market. The three products are indicated

Net income increased $5.1m from net loss of $2.2m for the year ended 31 May 2009 to net income of approximately $2.9m for the year ended 31 May

Sun Pharma’s units have raised their equity stake in Taro to 48.7% and voting rights to 65.8%, according to reports. The acquisition is in pursuant to the option

The Delhi High Court (HC) has rejected BMS’ plea for an interim injunction to temporarily stop Ranbaxy from producing and selling the drug in India. Justice Sunil Gaur

The company claims that the Promus Element Stent features a novel platinum chromium alloy and stent design, which combine to offer greater radial strength and flexibility while reducing

The company claims that in the trial, the activity of PA401 was benchmarked against other relevant treatment modalities including the PDE4 inhibitor roflumilast and the CXCR2 antagonist SCH527123.

Miochol-E is an injectable miotic pharmaceutical used during certain eye surgeries to constrict the pupil. As per the agreement, Novartis will provide technical assistance to Bausch + Lomb

In 1999-2000, with an investment of $40m, Symphony Capital was the single largest shareholder, reported Financial Express. However, three years ago, Symphony’s stake in Orchid Chemicals was brought